# OnCo record nct06015048 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06015048/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06015048", "NCT06015048" ;
  schema:name "A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors."@en ;
  schema:description "A phase 1/2 trial of Pyrotinib and Trastuzumab rezetecan in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06015048/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06015048> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2023-08-11" ;
  onco:cancers <https://onco.cc/cancers/metastatic-cancer/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/pyrotinib/>, <https://onco.cc/drugs/trastuzumab-rezetecan/> ;
  onco:companies <https://onco.cc/companies/hengrui/> .